Healthcare
Insmed Incorporated(INSM)
Live Price
Offline$98.61
+2.93% today
1Y Change
-5.96%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $29.43B
- Revenue Growth
- +66.7%
- EPS Growth
- -15.1%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Insmed Incorporated (INSM) is a Healthcare stock with a market cap of $29.43B and listed on NASDAQ. The stock last traded around $98.61 and down 6.0% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +66.7%, EPS growth of -15.1%, a dividend yield of 0.0%. What stands out right now is revenue +66.7%, EPS -15.1%, free cash flow -37.1% with operating margin -194.0% and ROIC -64.8%. Valuation already assumes a fairly strong business story at price/sales 48.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines INSM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+66.7% vs +7.6% peer median
Operating Margin
Below sector median
-194.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +66.7% and EPS is at -15.1%, with operating margin around -194.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -5.6% | -5.3% | -15.4% |
2026 Feb 19, 2026 | -43.9% | +2.4% | -6.8% | -10.6% |
2025 Oct 30, 2025 | -31.6% | -2.4% | -4.4% | +7.0% |
Benchmark Edge
INSM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INSM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INSM Max Drawdown
-56.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INSM and SPY.
Company Overview
Insmed Incorporated
NASDAQ Global Select
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
- Leadership
- William H. Lewis
- IPO Date
- Jun 1, 2000
- Employees
- 1.3k
- Street Address
- 700 US Highway 202/206
- Mailing
- Bridgewater, NJ, 08807
- Region
- Bridgewater, NJ, US
- Reporting Currency
- USD
- Investor Line
- 908 977 9900
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 48.5
- Price/Book
- 39.4
Growth
- Revenue
- +66.7%
- EPS
- -15.1%
- Free Cash Flow
- -37.1%
Profitability
- Gross Margin
- 79.4%
- Operating Margin
- -194.0%
- Net Margin
- -210.5%
- ROE
- -168.4%
- ROIC
- -64.8%
Balance Sheet
- Debt/Equity
- 1.04
- Current Ratio
- 3.83
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.